Want to see HK:1358 full AI Analyst Report?
PW Medtech Group Ltd. (1358) AI Stock Analysis
PW Medtech Group Ltd.
(HKEX:1358)
The score is primarily supported by a very strong, low-leverage balance sheet and continued profitability, but is held back by FY2025’s clear operating deceleration (revenue decline and margin compression) and weaker/less consistent cash generation. Technicals add additional pressure as the stock trades below major moving averages with negative MACD, while valuation is only moderately supported by the dividend yield against a relatively high P/E.
PW Medtech Group Ltd. (1358) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.28B
- Dividend Yield
- 3.46%
- Average Volume (3M)
- 526.49K
- Price to Earnings (P/E)
- 26.7
- Beta (1Y)
- 0.35
- Revenue Growth
- -1.64%
- EPS Growth
- -68.67%
- Country
- Hong Kong
- Employees
- 1,433
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
PW Medtech Group Ltd. Business Overview & Revenue Model
Company Description
Operating within the People's Republic of China, PW Medtech Group Limited is an investment holding company primarily engaged in the medical device industry. The company specializes in the manufacturing and distribution of a diverse portfolio of medic...
PW Medtech Group Ltd. Financial Statement Overview
Summary
Overall fundamentals are solid but weakening: the balance sheet is very conservative (minimal leverage) while FY2025 shows a meaningful slowdown with revenue down 5.05% and sharp margin compression (net margin 11.5% vs. 19.6% prior year). Cash flow remains positive, but free cash flow declined versus FY2024 and has shown volatility, reducing confidence in near-term earnings durability.
Income Statement
64PositiveBalance Sheet
88Very PositiveCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 803.62M | 823.50M | 768.90M | 675.08M | 536.83M | 271.40M |
| Gross Profit | 384.79M | 407.46M | 419.45M | 380.90M | 298.82M | 166.06M |
| EBITDA | 217.34M | 265.57M | 291.82M | 329.48M | 176.75M | 78.48M |
| Net Income | 43.08M | 94.37M | 150.78M | 153.18M | 106.04M | 739.12M |
Balance Sheet | ||||||
| Total Assets | 5.14B | 5.24B | 5.16B | 5.15B | 4.99B | 3.92B |
| Cash, Cash Equivalents and Short-Term Investments | 1.83B | 1.81B | 1.69B | 1.59B | 1.39B | 2.41B |
| Total Debt | 21.03M | 22.01M | 12.07M | 1.13M | 4.24M | 2.44M |
| Total Liabilities | 366.97M | 360.81M | 357.56M | 327.06M | 351.56M | 122.64M |
| Stockholders Equity | 3.89B | 3.95B | 3.97B | 4.04B | 3.95B | 3.79B |
Cash Flow | ||||||
| Free Cash Flow | 189.78M | 135.65M | 246.34M | 129.12M | 216.77M | 25.92M |
| Operating Cash Flow | 261.88M | 240.70M | 318.43M | 211.03M | 269.23M | 37.24M |
| Investing Cash Flow | 149.27M | 6.71M | -20.32M | -26.66M | -1.08B | 2.64B |
| Financing Cash Flow | -268.26M | -126.51M | -210.66M | 17.53M | -85.16M | -2.09B |
PW Medtech Group Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1358, the sentiment is Neutral. The current price of 0.90 is above the 20-day moving average (MA) of 0.89, below the 50-day MA of 0.90, and below the 200-day MA of 1.06, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 52.05 is Neutral, neither overbought nor oversold. The STOCH value of 43.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1358.
PW Medtech Group Ltd. Peers Comparison
Overall Rating
HK:360080Outperform
HK:692978Outperform
HK:106673Outperform
HK:669966Neutral- HK:135865Neutral
HK:150159Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:3600 | 80Outperform | HKD 6.83B | 10.03 | 20.11% | 3.96% | 12.50% | 44.44% |
| HK:6929 | 78Outperform | HKD 3.05B | 8.80 | 10.50% | 5.40% | 16.25% | 7.80% |
| HK:1066 | 73Outperform | HKD 15.40B | 9.67 | 5.64% | 4.95% | 7.47% | -26.89% |
| HK:6699 | 66Neutral | HKD 13.62B | 40.59 | 8.95% | 1.20% | ― | ― |
| HK:1358 | 65Neutral | HKD 1.28B | 26.67 | 1.10% | 3.46% | -1.64% | -68.67% |
| HK:1501 | 59Neutral | HKD 6.15B | 21.03 | 9.64% | 0.89% | 34.94% | 12.99% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1358 | PW Medtech Group Ltd. | 0.90 | -0.45 | -33.56% | |
| HK:1066 | Shandong Weigao Group Medical Polymer Co Class H | 3.40 | -1.70 | -33.33% | |
| HK:3600 | Modern Dental Group Limited | 7.32 | 2.22 | 43.53% | |
| HK:1501 | Shanghai Kindly Medical Instruments Co., Ltd. Class H | 29.12 | -1.60 | -5.20% | |
| HK:6699 | Angelalign Technology Inc. | 79.05 | 18.56 | 30.67% | |
| HK:6929 | OrbusNeich Medical Group Holdings Limited | 3.70 | -0.49 | -11.67% |
PW Medtech Group Ltd. Corporate Events
PW Medtech Subsidiary Moves to Delist from NEEQ with Minority Shareholder Protections
PW Medtech has disclosed that the board of its 53.10%-owned subsidiary Sichuan Ruijian Medical Technology has proposed a voluntary delisting of its shares from China’s National Equities Exchange and Quotations. The proposal will be put to share...
PW Medtech Subsidiary Enters Bankruptcy as Creditors Approve Asset Auction Plan
PW Medtech Group has disclosed that its indirect wholly owned subsidiary Xuzhou Yijia Medical Device Co., Ltd. is undergoing bankruptcy liquidation after a 2018 Supreme People’s Court judgment held it liable for principal and interest on a defa...
PW Medtech Earnings Slide Prompts Dividend Cut
PW Medtech Group Ltd. reported interim revenue of RMB394.1 million for the six months ended June 30, 2026, down 4.9% year-on-year, with gross profit falling 10.8% and margin declining to 48.2%. Profit for the period plunged 56.5% to RMB37.7 million,...
PW Medtech Declares Interim Dividend for First Half of 2026
PW Medtech Group Limited has declared an interim ordinary cash dividend of HKD 0.011 per share for the six months ended 30 June 2026, for the financial year ending 31 December 2026. Key dates include an ex-dividend date of 2 November 2026, a book clo...
PW Medtech Subsidiary Posts Higher Interim Profit Amid Rising Liabilities
PW Medtech’s subsidiary Sichuan Ruijian Medical reported modest but steady growth in its interim unaudited results for the six months ended 30 June 2026. Revenue rose 3.62% year-on-year to RMB 308.7 million, while profit for the period increase...
PW Medtech Sets August Board Meeting to Review Interim Results and Dividend
PW Medtech Group Ltd. has scheduled a board meeting for 28 August 2026 to review and approve the unaudited consolidated interim results for the six months ended 30 June 2026. At the same meeting, the board will also consider the declaration of an int...
PW Medtech warns of sharp profit drop on infusion set price cuts
PW Medtech has warned that its net profit for the six months ended June 30, 2026 is expected to fall sharply to RMB32 million–RMB49 million, down 43%–63% from RMB86.6 million a year earlier, with profit attributable to shareholders projec...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026